Page 75 - Read Online

Page 12 of 15 Fraser. J Transl Genet Genom 2018;2:21. I https://doi.org/10.20517/jtgg.2018.27

DECLARATIONS
Authors’ contributions
The author contributed solely to the article.

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2018.

REFERENCES
1. Zhou CK, Check DP, Lortet-Tieulent J, Laversanne M, Jemal A, et al. Prostate cancer incidence in 43 populations worldwide: an analysis of
time trends overall and by age group. Int J Cancer 2016;138:1388-400.
2. D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, et al. Biochemical outcome after radical prostatectomy, external beam
radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-74.
3. Litwin MS, Tan HJ. The diagnosis and treatment of prostate cancer: a review. JAMA 2017;317:2532-42.
4. Perlis N, Klotz L. Contemporary active surveillance: candidate selection, follow-up tools, and expected outcomes. Urol Clin North Am
2017;44:565-74.
5. Jackson WC, Suresh K, Tumati V, Allen SG, Dess RT, et al. Intermediate endpoints after postprostatectomy radiotherapy: 5-year distant me-
tastasis to predict overall survival. Eur Urol 2018;74:413-9.
6. Ellwood-Yen K, Wongvipat J, Sawyers C. Transgenic mouse model for rapid pharmacodynamic evaluation of antiandrogens. Cancer Res
2006;66:10513-6.
7. Hsieh AC, Small EJ, Ryan CJ. Androgen-response elements in hormone-refractory prostate cancer: implications for treatment development.
Lancet Oncol 2007;8:933-9.
8. Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, et al. Emerging landscape of oncogenic signatures across human cancers. Nat
Genet 2013;45:1127-33.
9. Espiritu SMG, Liu LY, Rubanova Y, Bhandari V, Holgersen EM, et al. The evolutionary landscape of localized prostate cancers drives clini-
cal aggression. Cell 2018;173:1003-13.
10. Fraser M, Sabelnykova VY, Yamaguchi TN, Heisler LE, Livingstone J, et al. Genomic hallmarks of localized, non-indolent prostate cancer.
Nature 2017;541:359-64.
11. Cooperberg MR, Erho N, Chan JM, Feng FY, Fishbane N, et al. The diverse genomic landscape of clinically low-risk prostate cancer. Eur
Urol 2018;74:444-52.
12. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, et al. Integrative clinical genomics of advanced prostate cancer. Cell
2015;161:1215-28.
13. Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, et al. The long tail of oncogenic drivers in prostate cancer. Nat Genet 2018;50:645-51.
14. Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, et al. Genomic hallmarks and structural variation in metastatic prostate cancer. Cell
2018;174:758-69.
15. Taylor RA, Fraser M, Livingstone J, Espiritu SM, Thorne H, et al. Germline BRCA2 mutations drive prostate cancers with distinct evolu-
tionary trajectories. Nat Commun 2017;8:13671.
16. Amin Al Olama A, Benlloch S, Antoniou AC, Giles GG, Severi G, et al. Risk analysis of prostate cancer in PRACTICAL, a multinational